Pages that link to "Q35650273"
Jump to navigation
Jump to search
The following pages link to Pre-Clinical Assessment of 177Lu-Labeled Trastuzumab Targeting HER2 for Treatment and Management of Cancer Patients with Disseminated Intraperitoneal Disease (Q35650273):
Displaying 9 items.
- HER2 expression beyond breast cancer: therapeutic implications for gynecologic malignancies (Q26822730) (← links)
- Targeted radionuclide therapy with A 177Lu-labeled anti-HER2 nanobody (Q33686807) (← links)
- D-Amino acid peptide residualizing agents bearing N-hydroxysuccinimido- and maleimido-functional groups and their application for trastuzumab radioiodination (Q34718122) (← links)
- Mechanisms of Cell Killing Response from Low Linear Energy Transfer (LET) Radiation Originating from (177)Lu Radioimmunotherapy Targeting Disseminated Intraperitoneal Tumor Xenografts (Q36939290) (← links)
- Targeted therapy in uterine serous carcinoma: an aggressive variant of endometrial cancer (Q37699264) (← links)
- Radioimmunotherapy for peritoneal cancers (Q38096059) (← links)
- General overview of radioimmunotherapy of solid tumors (Q38103579) (← links)
- Preparation of clinical-scale 177 Lu-Rituximab: Optimization of protocols for conjugation, radiolabeling, and freeze-dried kit formulation (Q48258781) (← links)
- Theranostic pretargeted radioimmunotherapy of internalizing solid tumor antigens in human tumor xenografts in mice: Curative treatment of HER2-positive breast carcinoma (Q59133661) (← links)